12月9日 - ** 药物开发商TuHURA Biosciences的HURA.O股价暴跌36.9%至1.25美元
** HURA 在 (link) 签订协议，以每股 1.65 美元的购买价在注册直接发行中出售约 950 万股股票、A 系列认股权证和 B 系列认股权证，募集资金总额为 1560 万美元。
** H.C. Wainwright 是此次发行的独家首席配售代理
** 预计发行将分三批完成
** 发行收益将用于运营资本和一般用途
** 覆盖该股的三位分析师均给予 "买入 "评级；中位数PT值为9.13美元--数据由LSEG编制
** 截至上次收盘，HURA股价年累计下跌51.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.